Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedImmune, Abpro’s Unspecific Plans For Bispecific Antibody Collaboration

Executive Summary

The AstraZeneca affiliate and the Boston-area synthetic biology specialist are creating a spinout to develop a bispecific antibody targeting Ang2 and VEGF for undisclosed indications. Cancer and wet age-related macular degeneration seem likely areas of focus.

Advertisement

Related Content

Deal Watch: Merck Digging Into Epigenetics With Proteros Partnership
Roche's Post-Avastin Strategy Stumbles As Vanucizumab Fails In Phase II
AstraZeneca’s Seasoned Dealmaker Grady On Strategy To Grow Pipeline
Roche’s pRED Team Reviews R&D Wish List As Firm Continues Push To Diversify
Ophthotech Underscores Limitations Of Anti-VEGFs in Wet AMD
It’s Differentiate Or Perish At MedImmune’s Oncology iMED

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel